Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01031446 · ClinicalTrials.gov registry record · Phase 1
Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer
A Phase 1 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT01031446 is a Phase 1 study that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 55 participants.
The verdict
NCT01031446, a Phase 1 study, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving cisplatin and paclitaxel together with everolimus may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects of giving cisplatin and paclitaxel together with everolimus and to see how well it works in treating patients with metastatic breast cancer.
Interventions
- OTHER laboratory biomarker analysis
- DRUG cisplatin
- DRUG paclitaxel
- DRUG everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2009-10 |
| Est. Completion | 2017-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01031446
The ClinicalTrials.gov registry entry for NCT01031446 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01031446 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01031446 about?
NCT01031446 is a clinical study titled "Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer". RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and b...
What is the current status of trial NCT01031446?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2009-10. Estimated completion is 2017-08.
What interventions are being tested in trial NCT01031446?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cisplatin (DRUG), paclitaxel (DRUG), everolimus (DRUG).
Who is sponsoring clinical trial NCT01031446?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.